To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al

MeSH terms

• Acrylamides / therapeutic use
• Aminopyridines
• Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
• Aromatase Inhibitors* / therapeutic use
• Benzimidazoles
• Breast Neoplasms* / drug therapy
• Breast Neoplasms* / mortality
• Breast Neoplasms* / pathology
• Female
• Humans
• Receptor, ErbB-2* / antagonists & inhibitors
• Receptor, ErbB-2* / metabolism
• Receptors, Estrogen / metabolism
• Receptors, Progesterone / metabolism